"Forsyth Barr estimated that a Spark share price of below $4.80 between the 17th and 30th of April would likely trigger the EBOS exit from the ACWI. Funnily enough the Spark share price does indeed slump below that level during that period. We cannot know for sure but if you were running an arbitrage hedge fund a possible trade would be to short sell EBOS now in the expectation of buying it back cheaper when the 9.7 million of index selling hits the market. But to make sure EBOS does leave the index, the arbitrage hedge fund also sells shares in Spark to contribute towards a weaker share price." https://www.goodreturns.co.nz/articl...or+30+Apr+2024
there it is combined entity will be a 3.5billion company to take on transmedic
anyway i guess it opens up the possibilty of ebos buying the merged entity
PGC merger completed today and at 39c ( 100% gains at the moment for those that spec on pgc ) I wonder if EBO will take a look at the bigger company after there got some runs on the board.
interesting how pharmacies might have there uber moment and be disrupted
The Chemist Warehouse deal is a sideshow: pharmacies are ripe for bigger disruption
Chemist Warehouse isn’t even Australia’s biggest pharmacy group. That’s EBOS, which runs brands including Terry White, healthSAVE, Cincotta Discount Chemist, Mega Save Chemist, Max Value Pharmacy, BetterBuy Pharmacy, MyMedical Pharmacy and Good Price Pharmacy Warehouse.
EBOS Group Limited (“EBOS”) notes media commentary (Financial Review – Street Talk, 15 July 2024) speculating on EBOS’ interest in the potential sale of pet food business Prime100.
EBOS advises it will not be participating in any potential forthcoming sale of Prime100.
• Revenue of $13.2 billion (up 7.8%)
• Underlying EBITDA of $624.3 million (up 7.3%)
• Underlying NPATof $303.4 million (up 7.7%)
• Underlying EPS of 157.9 cents (up 6.8%)
• Final dividend declared of NZ 61.5 cents per share, bringing total dividends declared for theyear to NZ 118.5 cents per share (up 7.7%)
• Continued strong earnings growth in Healthcare and Animal Care segments with HealthcareUnderlying EBITDA up 6.0% and Animal Care Underlying EBITDA up 13.2%
• Significant investments undertaken in line with our strategy of investing for growth, aspreviously announced we increased our shareholding in Transmedic and completed theacquisition of Superior Pet Food Co. (Superior). In addition, we completed four small bolt-onacquisitions in the Medical Technology and Medical Consumables businesses across ANZ andSoutheast Asia1
• ROCE increased by 20 bp to 15.3%, in line with target
• Net Debt : EBITDA reduced to 1.89x compared to 2.06x at December 2023
• To assist investors EBOS is providing guidance for FY25 that the Group expects to generateUnderlying EBITDA of between $575 million to $600 million
Reply With Quote
Originally Posted by bull....
Bookmarks